GlassScriptPhysician profile
Recaredo Berbano
NPI 1942275748
$146,096.37
in general payments reported to CMS, 2019-2025
50 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $46K · 2021: $20K · 2022: $7,089 · 2023: $2,381 · 2024: $2,161 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,725 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,724.72 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54,032.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $25,908.84 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $23,214.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,462.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $12,577.93 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $3,574.54 | 2019-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $2,537.05 | 2019-2020 | |
| Mannkind Corporation | $830.49 | 2019-2025 | |
| Amgen INC. | $753.59 | 2019-2021 | |
| Intuity Medical INC | $543.48 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Esperion Therapeutics, INC. | $541.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $474.12 | 2023-2025 | |
| Madrigal Pharmaceuticals | $459.64 | 2025 | Rezdiffra |
| Insulet Corporation | $324.59 | 2019-2025 | Omnipod |
| Radius Health, INC. | $298.95 | 2019-2021 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $297.04 | 2023-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Amarin Pharma, INC. | $266.31 | 2019-2021 | |
| Antares Pharma, INC. | $257.04 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $253.17 | 2019-2022 | |
| Astellas Pharma US INC | $234.69 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $233.77 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $230.06 | 2019-2022 | |
| Cequr Corporation | $184.69 | 2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $177.01 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $175.86 | 2024 | |
| Ascendis Pharma Endocrinology INC | $167.81 | 2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $109.69 | 2019-2020 | |
| Medtronic Minimed, INC. | $103.28 | 2019-2020 | |
| Viiv Healthcare Company | $94.44 | 2024-2025 | Apretude |
| Dexcom, INC. | $84.16 | 2023-2024 | Dexcom G6 Transmitter |
| Valeritas, INC. | $80.27 | 2019 | |
| Shire North American Group INC | $73.54 | 2019 | |
| Ibsa Pharma INC. | $63.14 | 2020 | |
| Tandem Diabetes Care, INC. | $41.43 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $41.01 | 2023 | |
| Medtronic, INC. | $40.97 | 2024-2025 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $40.39 | 2019 | |
| Kvk-Tech, INC. | $40.27 | 2019-2021 | |
| Pfizer INC. | $38.51 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $37.69 | 2021 | |
| Hologic Sales and Service, LLC | $35.93 | 2024 | Aptima |
| Alexion Pharmaceuticals, INC. | $35.53 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $18.17 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $16.67 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.61 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.23 | 2019 | |
| Horizon Therapeutics Plc | $16.00 | 2023 | Tepezza |
| Senseonics, Incorporated | $16.00 | 2019 | |
| Vifor Pharma, INC. | $12.41 | 2019 | |
| Eisai INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Recaredo Berbano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.